Barclays: Amicus Therapeutics FOLD Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Venta |
-1,338,482
| Cerradas | -USD 19.4 M | – | 5446 |
|
|
2026
Q1 | USD 19.4 M | Compra |
1,338,482
+203,843
| +18% | +USD 2.92 M | 0.01% | 1122 |
|
|
2025
Q4 | USD 16.2 M | Compra |
1,134,639
+165,117
| +17% | +USD 1.62 M | ﹤0.01% | 1367 |
|
|
2025
Q3 | USD 7.64 M | Venta |
969,522
-213,213
| -18% | -USD 1.52 M | ﹤0.01% | 1869 |
|
|
2025
Q2 | USD 6.78 M | Compra |
1,182,735
+546,637
| +86% | +USD 3.53 M | ﹤0.01% | 1859 |
|
|
2025
Q1 | USD 5.19 M | Venta |
636,098
-28,562
| -4% | -USD 264 k | ﹤0.01% | 1881 |
|
|
2024
Q4 | USD 6.26 M | Compra |
664,660
+32,955
| +5% | +USD 343 k | ﹤0.01% | 1950 |
|
|
2024
Q3 | USD 6.75 M | Compra |
631,705
+185,314
| +42% | +USD 2.02 M | ﹤0.01% | 1796 |
|
|
2024
Q2 | USD 4.43 M | Compra |
446,391
+97,454
| +28% | +USD 1 M | ﹤0.01% | 1620 |
|
|
2024
Q1 | USD 4.11 M | Venta |
348,937
-378,838
| -52% | -USD 4.84 M | ﹤0.01% | 1999 |
|
|
2023
Q4 | USD 10.3 M | Compra |
727,775
+315,339
| +76% | +USD 3.58 M | ﹤0.01% | 1495 |
|
|
2023
Q3 | USD 5.02 M | Compra |
412,436
+7,096
| +2% | +USD 91.5 k | ﹤0.01% | 1313 |
|
|
2023
Q2 | USD 5.09 M | Venta |
405,340
-51,810
| -11% | -USD 615 k | ﹤0.01% | 1335 |
|
|
2023
Q1 | USD 5.07 M | Compra |
457,150
+35,330
| +8% | +USD 435 k | ﹤0.01% | 1533 |
|
|
2022
Q4 | USD 5.15 M | Compra |
421,820
+16,299
| +4% | +USD 183 k | ﹤0.01% | 1602 |
|
|
2022
Q3 | USD 4.23 M | Compra |
405,521
+387,185
| +2,112% | +USD 4.31 M | ﹤0.01% | 1266 |
|
|
2022
Q2 | USD 197 k | Venta |
18,336
-88,882
| -83% | -USD 732 k | ﹤0.01% | 3426 |
|
|
2022
Q1 | USD 1.02 M | Venta |
107,218
-219,041
| -67% | -USD 2.05 M | ﹤0.01% | 2382 |
|
|
2021
Q4 | USD 3.77 M | Venta |
326,259
-125,879
| -28% | -USD 1.4 M | ﹤0.01% | 1916 |
|
|
2021
Q3 | USD 4.32 M | Compra |
452,138
+228,331
| +102% | +USD 2.34 M | ﹤0.01% | 1730 |
|
|
2021
Q2 | USD 2.16 M | Venta |
223,807
-207,946
| -48% | -USD 2.03 M | ﹤0.01% | 2140 |
|
|
2021
Q1 | USD 4.27 M | Compra |
431,753
+229,812
| +114% | +USD 3.56 M | ﹤0.01% | 1651 |
|
|
2020
Q4 | USD 4.66 M | Venta |
201,941
-238,687
| -54% | -USD 4.88 M | ﹤0.01% | 1560 |
|
|
2020
Q3 | USD 6.22 M | Venta |
440,628
-38,757
| -8% | -USD 565 k | ﹤0.01% | 1275 |
|
|
2020
Q2 | USD 7.23 M | Venta |
479,385
-81,956
| -15% | -USD 999 k | 0.01% | 1137 |
|
|
2020
Q1 | USD 5.19 M | Venta |
561,341
-162,566
| -22% | -USD 1.55 M | ﹤0.01% | 1430 |
|
|
2019
Q4 | USD 7.05 M | Compra |
723,907
+497,092
| +219% | +USD 4.55 M | ﹤0.01% | 1678 |
|
|
2019
Q3 | USD 1.82 M | Compra |
226,815
+77,517
| +52% | +USD 841 k | ﹤0.01% | 2987 |
|
|
2019
Q2 | USD 1.86 M | Compra |
149,298
+65,611
| +78% | +USD 833 k | ﹤0.01% | 3008 |
|
|
2019
Q1 | USD 1.14 M | Compra |
83,687
+59,341
| +244% | +USD 725 k | ﹤0.01% | 3270 |
|
|
2018
Q4 | USD 233 k | Venta |
24,346
-75,368
| -76% | -USD 828 k | ﹤0.01% | 4469 |
|
|
2018
Q3 | USD 1.2 M | Compra |
99,714
+85,854
| +619% | +USD 1.2 M | ﹤0.01% | 3456 |
|
|
2018
Q2 | USD 216 k | Venta |
13,860
-32,281
| -70% | -USD 488 k | ﹤0.01% | 4653 |
|
|
2018
Q1 | USD 693 k | Compra |
46,141
+14,135
| +44% | +USD 215 k | ﹤0.01% | 3620 |
|
|
2017
Q4 | USD 460 k | Compra |
32,006
+28,174
| +735% | +USD 387 k | ﹤0.01% | 3921 |
|
|
2017
Q3 | USD 58 k | Venta |
3,832
-6,564
| -63% | -USD 86.8 k | ﹤0.01% | 5276 |
|
|
2017
Q2 | USD 105 k | Compra |
10,396
+4,323
| +71% | +USD 34.8 k | ﹤0.01% | 4865 |
|
|
2017
Q1 | USD 43 k | Venta |
6,073
-217,699
| -97% | -USD 1.38 M | ﹤0.01% | 5423 |
|
|
2016
Q4 | USD 1.11 M | Compra |
223,772
+86,404
| +63% | +USD 598 k | ﹤0.01% | 2643 |
|
|
2016
Q3 | USD 1.02 M | Compra |
+137,368
| Nuevas | +USD 928 k | ﹤0.01% | 2606 |
|
|
2016
Q2 | – | Venta |
-1,175
| Cerradas | -USD 9 k | – | 6406 |
|
|
2016
Q1 | USD 9 k | Venta |
1,175
-15,856
| -93% | -USD 112 k | ﹤0.01% | 5503 |
|
|
2015
Q4 | USD 153 k | Venta |
17,031
-15,919
| -48% | -USD 143 k | ﹤0.01% | 4121 |
|
|
2015
Q3 | USD 429 k | Compra |
32,950
+31,053
| +1,637% | +USD 487 k | ﹤0.01% | 3490 |
|
|
2015
Q2 | USD 27 k | Compra |
1,897
+783
| +70% | +USD 9.41 k | ﹤0.01% | 5501 |
|
|
2015
Q1 | USD 11 k | Compra |
1,114
+410
| +58% | +USD 3.61 k | ﹤0.01% | 6173 |
|
|
2014
Q4 | USD 6 k | Compra |
704
+563
| +399% | +USD 3.86 k | ﹤0.01% | 6922 |
|
|
2014
Q3 | USD 1 k | Venta |
141
-43,191
| -100% | -USD 226 k | ﹤0.01% | 7498 |
|
|
2014
Q2 | USD 130 k | Compra |
43,332
+42,019
| +3,200% | +USD 98.6 k | ﹤0.01% | 5211 |
|
|
2014
Q1 | USD 2 k | Compra |
1,313
+516
| +65% | +USD 1.29 k | ﹤0.01% | 7399 |
|
|
2013
Q4 | USD 1 k | Venta |
797
-1,346
| -63% | -USD 2.95 k | ﹤0.01% | 7438 |
|
|
2013
Q3 | USD 4 k | Venta |
2,143
-763
| -26% | -USD 1.92 k | ﹤0.01% | 7033 |
|
|
2013
Q2 | USD 7 k | Sin cambios |
2,906
| – | – | ﹤0.01% | 7255 |
|
Otros fondos que tienen FOLD en su portafolio
Posición de Barclays en FOLD: resumen de T2 2026
Barclays liquidó su posición en Amicus Therapeutics (FOLD) en T2 2026: cerró una participación de 1,338,482 acciones, con ventas por un valor estimado de USD 19.4 M.
Barclays reportó por primera vez una posición en FOLD en T2 2013 y la mantuvo en 51 trimestres. La posición alcanzó su máximo de USD 19.4 M en T1 2026. Al cierre de T2 2026, 2 fondos que sigue Wall St. Rank mantienen una posición en FOLD.
- Barclays reportó que ya no tenía una posición en Amicus Therapeutics al cierre de T2 2026, después de venderla por completo durante el trimestre.
- Barclays vendió 1,338,482 acciones de Amicus Therapeutics en T2 2026, por un valor estimado de USD 19.4 M.
- Barclays reportó por primera vez una posición en Amicus Therapeutics en T2 2013 y la mantuvo en 51 trimestres.
- La posición de Barclays en Amicus Therapeutics alcanzó su máximo de USD 19.4 M en T1 2026.
- Al cierre de T2 2026, 2 fondos que sigue Wall St. Rank tenían Amicus Therapeutics en su portafolio.
Según el informe 13F de Barclays correspondiente a T2 2026, presentado el 14 ago 2026.